Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers.

Wijma RA, Huttner A, van Dun S, Kloezen W, Abbott IJ, Muller AE, Koch BCP, Mouton JW.

Int J Antimicrob Agents. 2019 Aug 2. pii: S0924-8579(19)30207-9. doi: 10.1016/j.ijantimicag.2019.07.018. [Epub ahead of print]

PMID:
31382030
2.

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management.

Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF.

J Fungi (Basel). 2019 Jul 1;5(3). pii: E55. doi: 10.3390/jof5030055. Review.

3.

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.

Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM.

J Antimicrob Chemother. 2019 Jun 24. pii: dkz267. doi: 10.1093/jac/dkz267. [Epub ahead of print]

PMID:
31236595
4.

Development and validation of a fast and sensitive UHPLC-DAD assay for the quantification of nitrofurantoin in plasma and urine.

Wijma RA, Hoogtanders KEJ, Croes S, Mouton JW, Brüggemann RJM.

J Pharm Biomed Anal. 2019 Sep 10;174:161-167. doi: 10.1016/j.jpba.2019.05.054. Epub 2019 May 28.

PMID:
31170629
5.

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Smit C, Wasmann RE, Wiezer MJ, van Dongen HPA, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Pharm Res. 2019 May 30;36(8):112. doi: 10.1007/s11095-019-2651-2.

6.

Development and multicentre validation of an agar-based screening method for echinocandin susceptibility testing of Aspergillus species.

Meletiadis J, Siopi M, Kanioura L, Jørgensen KM, Perlin DS, Mouton JW, Arendrup MC.

J Antimicrob Chemother. 2019 Aug 1;74(8):2247-2254. doi: 10.1093/jac/dkz154.

PMID:
31106352
7.

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.

Smit C, Wasmann RE, Goulooze SC, Hazebroek EJ, Van Dongen EPA, Burgers DMT, Mouton JW, Brüggemann RJM, Knibbe CAJ.

Clin Pharmacokinet. 2019 Apr 24. doi: 10.1007/s40262-019-00762-4. [Epub ahead of print]

PMID:
31016671
8.

Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision-authors' response.

Mouton JW, Meletiadis J, Voss A, Turnidge J.

J Antimicrob Chemother. 2019 Jun 1;74(6):1761-1762. doi: 10.1093/jac/dkz142. No abstract available.

PMID:
30989229
9.

In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Siopi M, Mouton JW, Pournaras S, Meletiadis J.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02673-18. doi: 10.1128/AAC.02673-18. Print 2019 Jun.

PMID:
30962332
10.

Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know?

Wijma RA, Fransen F, Muller AE, Mouton JW.

Drug Resist Updat. 2019 Mar;43:1-9. doi: 10.1016/j.drup.2019.03.001. Epub 2019 Mar 20. Review.

PMID:
30947111
11.

The pharmacokinetics of nitrofurantoin in healthy female volunteers: a randomized crossover study.

Huttner A, Wijma RA, Stewardson AJ, Olearo F, Von Dach E, Harbarth S, Brüggemann RJM, Mouton JW, Muller AE.

J Antimicrob Chemother. 2019 Jun 1;74(6):1656-1661. doi: 10.1093/jac/dkz095.

PMID:
30859184
12.
13.

Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.

Melchers MJ, Teague J, Warn P, Hansen J, Bernardini F, Wach A, Obrecht D, Dale GE, Mouton JW.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01699-18. doi: 10.1128/AAC.01699-18. Print 2019 Mar.

PMID:
30642931
14.

Erratum for Meletiadis et al., "Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone".

Meletiadis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02184-18. doi: 10.1128/AAC.02184-18. Print 2018 Dec. No abstract available.

15.

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group .

Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.

PMID:
30462182
16.

High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers - authors' response.

Wijma RA, Koch BCP, van Gelder T, Mouton JW.

Clin Microbiol Infect. 2019 Feb;25(2):256-257. doi: 10.1016/j.cmi.2018.10.017. Epub 2018 Nov 9. No abstract available.

PMID:
30415093
17.

Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.

Tsala M, Vourli S, Georgiou PC, Pournaras S, Daikos GRL, Mouton JW, Meletiadis J.

J Antimicrob Chemother. 2019 Feb 1;74(2):387-394. doi: 10.1093/jac/dky422.

PMID:
30376071
18.

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility.

Lellouche J, Schwartz D, Elmalech N, Ben Dalak MA, Temkin E, Paul M, Geffen Y, Yahav D, Eliakim-Raz N, Durante-Mangoni E, Iossa D, Bernardo M, Daikos GL, Skiada A, Pantazatou A, Antoniadou A, Mouton JW, Carmeli Y; AIDA study group.

Clin Microbiol Infect. 2019 Jun;25(6):711-716. doi: 10.1016/j.cmi.2018.09.014. Epub 2018 Oct 4.

PMID:
30291971
19.

How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates.

Guinea J, Verweij PE, Meletiadis J, Mouton JW, Barchiesi F, Arendrup MC; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).

Clin Microbiol Infect. 2019 Jun;25(6):681-687. doi: 10.1016/j.cmi.2018.09.008. Epub 2018 Sep 28. Review.

PMID:
30268672
20.

An alternative strategy for combination therapy: Interactions between polymyxin B and non-antibiotics.

Otto RG, van Gorp E, Kloezen W, Meletiadis J, van den Berg S, Mouton JW.

Int J Antimicrob Agents. 2019 Jan;53(1):34-39. doi: 10.1016/j.ijantimicag.2018.09.003. Epub 2018 Sep 19.

PMID:
30240838
21.

Soup with or without meatballs: Impact of nutritional factors on the MIC, kill-rates and growth-rates.

Mouton JW.

Eur J Pharm Sci. 2018 Dec 1;125:23-27. doi: 10.1016/j.ejps.2018.09.008. Epub 2018 Sep 12.

PMID:
30218696
22.

Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline.

Wijma RA, Huttner A, Koch BCP, Mouton JW, Muller AE.

J Antimicrob Chemother. 2018 Nov 1;73(11):2916-2926. doi: 10.1093/jac/dky255.

PMID:
30184207
23.

Variation of MIC measurements: the contribution of strain and laboratory variability to measurement precision.

Mouton JW, Meletiadis J, Voss A, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2374-2379. doi: 10.1093/jac/dky232.

PMID:
30137390
24.

MIC-based dose adjustment: facts and fables-authors' response.

Mouton JW, Muller AE, Canton R, G Giske C, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Sep 1;73(9):2585-2586. doi: 10.1093/jac/dky195. No abstract available.

PMID:
30137389
25.

Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, Harbarth S; COMBACTE-NET Consortium.

Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.

26.

Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.

de Velde F, Mouton JW, de Winter BCM, van Gelder T, Koch BCP.

Pharmacol Res. 2018 Aug;134:280-288. doi: 10.1016/j.phrs.2018.07.005. Epub 2018 Jul 6. Review.

27.

The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.

PMID:
30025972
28.

Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative infections: A pilot study.

Gautam V, Shafiq N, Mouton JW, Malhotra S, Kaur S, Ray P.

Indian J Med Res. 2018 Apr;147(4):407-412. doi: 10.4103/ijmr.IJMR_1464_16.

29.

Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion.

van den Bijllaardt W, Schijffelen MJ, Bosboom RW, Cohen Stuart J, Diederen B, Kampinga G, Le TN, Overdevest I, Stals F, Voorn P, Waar K, Mouton JW, Muller AE.

J Antimicrob Chemother. 2018 Sep 1;73(9):2380-2387. doi: 10.1093/jac/dky214.

PMID:
29982660
30.

Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement.

van Mens SP, Ten Doesschate T, Kluytmans-van den Bergh MFQ, Mouton JW, Rossen JWA, Verhulst C, Bonten MJM, Kluytmans JAJW.

Int J Antimicrob Agents. 2018 Nov;52(5):678-681. doi: 10.1016/j.ijantimicag.2018.06.014. Epub 2018 Jun 27.

PMID:
29958976
31.

Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.

Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J.

J Antimicrob Chemother. 2018 Aug 1;73(8):2274. doi: 10.1093/jac/dky218. No abstract available.

PMID:
29800383
32.

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects.

Muller AE, Punt N, Engelhardt M, Schmitt-Hoffmann AH, Mouton JW.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):781-787. doi: 10.1002/cpdd.465. Epub 2018 May 16.

33.

Two versus five days of antibiotics after appendectomy for complex acute appendicitis (APPIC): study protocol for a randomized controlled trial.

van den Boom AL, de Wijkerslooth EML, van Rosmalen J, Beverdam FH, Boerma EG, Boermeester MA, Bosmans JWAM, Burghgraef TA, Consten ECJ, Dawson I, Dekker JWT, Emous M, van Geloven AAW, Go PMNYH, Heijnen LA, Huisman SA, Jean Pierre D, de Jonge J, Kloeze JH, Koopmanschap MA, Langeveld HR, Luyer MDP, Melles DC, Mouton JW, van der Ploeg APT, Poelmann FB, Ponten JEH, van Rossem CC, Schreurs WH, Shapiro J, Steenvoorde P, Toorenvliet BR, Verhelst J, Versteegh HP, Wijnen RMH, Wijnhoven BPL.

Trials. 2018 May 2;19(1):263. doi: 10.1186/s13063-018-2629-0.

34.

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S.

JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.

35.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
36.

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method.

Arendrup MC, Meletiadis J, Zaragoza O, Jørgensen KM, Marcos-Zambrano LJ, Kanioura L, Cuenca-Estrella M, Mouton JW, Guinea J.

Clin Microbiol Infect. 2018 Nov;24(11):1200-1204. doi: 10.1016/j.cmi.2018.02.021. Epub 2018 Mar 2.

PMID:
29505881
37.

A New Marker of Echinocandin Activity in an In Vitro Pharmacokinetic/Pharmacodynamic Model Correlates with an Animal Model of Aspergillus fumigatus Infection.

Meletiadis J, Siopi M, Tsakris A, Mouton JW, Pournaras S.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02322-17. doi: 10.1128/AAC.02322-17. Print 2018 May.

38.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
39.

Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.

Ortiz Zacarías NV, Dijkmans AC, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Kamerling IMC, Stevens J.

Pharmacol Res Perspect. 2018 Feb;6(1). doi: 10.1002/prp2.378.

40.

Exploring colistin pharmacodynamics against Klebsiella pneumoniae: a need to revise current susceptibility breakpoints.

Tsala M, Vourli S, Georgiou PC, Pournaras S, Tsakris A, Daikos GL, Mouton JW, Meletiadis J.

J Antimicrob Chemother. 2018 Apr 1;73(4):953-961. doi: 10.1093/jac/dkx522.

PMID:
29377998
41.

Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model.

Abbott IJ, Meletiadis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, Peleg AY, Mouton JW.

J Antimicrob Chemother. 2018 Mar 1;73(3):709-719. doi: 10.1093/jac/dkx441.

PMID:
29253153
42.

MIC-based dose adjustment: facts and fables.

Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Mar 1;73(3):564-568. doi: 10.1093/jac/dkx427.

PMID:
29216348
43.

Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.

De Velde F, De Winter BCM, Koch BCP, Van Gelder T, Mouton JW; COMBACTE-NET consortium.

J Antimicrob Chemother. 2018 Feb 1;73(2):469-476. doi: 10.1093/jac/dkx376.

PMID:
29136160
44.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. No abstract available.

PMID:
29112717
45.

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerling IMC.

Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24. doi: 10.3390/antibiotics6040024. Review.

46.

Extended-spectrum β-lactamase (ESBL) polymerase chain reaction assay on rectal swabs and enrichment broth for detection of ESBL carriage.

van den Bijllaardt W, Janssens MM, Buiting AG, Muller AE, Mouton JW, Verweij JJ.

J Hosp Infect. 2018 Mar;98(3):264-269. doi: 10.1016/j.jhin.2017.10.014. Epub 2017 Oct 26.

PMID:
29080706
47.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):134-142. doi: 10.1093/jac/dkx354. Erratum in: J Antimicrob Chemother. 2018 Jan 1;73(1):263.

PMID:
29048485
48.

Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.

Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3325-3333. doi: 10.1093/jac/dkx319.

PMID:
29029256
49.

Pharmacodynamics of fosfomycin against ESBL- and/or carbapenemase-producing Enterobacteriaceae.

Fransen F, Hermans K, Melchers MJB, Lagarde CCM, Meletiadis J, Mouton JW.

J Antimicrob Chemother. 2017 Dec 1;72(12):3374-3381. doi: 10.1093/jac/dkx328.

PMID:
29029067
50.

Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?

Bos AC, Mouton JW, van Westreenen M, Andrinopoulou ER, Janssens HM, Tiddens HAWM.

J Antimicrob Chemother. 2017 Dec 1;72(12):3435-3442. doi: 10.1093/jac/dkx293.

PMID:
29029057

Supplemental Content

Loading ...
Support Center